share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股SEC公告 ·  10/01 16:11
Moomoo AI 已提取核心訊息
Cassava Sciences, Inc., a biopharmaceutical company, has filed an amendment to its original Form 8-K report with the SEC, detailing the compensation terms for its newly appointed CEO, Richard Barry. The amendment, dated October 1, 2024, follows the initial announcement on September 9, 2024, which did not include these details. Barry's appointment as CEO was effective as of September 6, 2024. The Board approved an executive employment agreement that includes an initial base salary of $675,000 retroactive to July 15, 2024, a target annual bonus of 60% of his base salary, and a stock option award to purchase 600,000 shares at $27.42 per share. The options will vest over four years, contingent upon Barry's continued employment. Additionally, the agreement outlines severance benefits in the event of termination without cause or resignation for good reason, including a year's base salary and medical plan coverage. The full terms of the Employment Agreement are detailed in Exhibit 10.1 attached to the amendment.
Cassava Sciences, Inc., a biopharmaceutical company, has filed an amendment to its original Form 8-K report with the SEC, detailing the compensation terms for its newly appointed CEO, Richard Barry. The amendment, dated October 1, 2024, follows the initial announcement on September 9, 2024, which did not include these details. Barry's appointment as CEO was effective as of September 6, 2024. The Board approved an executive employment agreement that includes an initial base salary of $675,000 retroactive to July 15, 2024, a target annual bonus of 60% of his base salary, and a stock option award to purchase 600,000 shares at $27.42 per share. The options will vest over four years, contingent upon Barry's continued employment. Additionally, the agreement outlines severance benefits in the event of termination without cause or resignation for good reason, including a year's base salary and medical plan coverage. The full terms of the Employment Agreement are detailed in Exhibit 10.1 attached to the amendment.
cassava sciences,一家生物製藥公司,已向證監會提交了對原8-k表格報告的修正,詳細說明新任CEO理查德·巴里的補償條款。該修正案的日期爲2024年10月1日,這是繼2024年9月9日的首次公告後的補充說明,首次公告中並未包括這些細節。巴里被任命爲CEO的日期爲2024年9月6日。董事會批准了一份行政僱傭協議,包括從2024年7月15日開始的67.5萬美元的初步基本工資、相當於基本工資60%的目標年度獎金以及購買60萬股股票的期權獎勵,每股27.42美元。這些期權將在四年內解鎖,取決於巴里的繼續僱傭。此外,協議規定了無正當理由解僱或出於正當理由辭職時的解聘福利,包括一年的基本工資和醫療計劃保障。僱傭協議的全部條款詳細列在附在修正案上的第10.1展示文檔中。
cassava sciences,一家生物製藥公司,已向證監會提交了對原8-k表格報告的修正,詳細說明新任CEO理查德·巴里的補償條款。該修正案的日期爲2024年10月1日,這是繼2024年9月9日的首次公告後的補充說明,首次公告中並未包括這些細節。巴里被任命爲CEO的日期爲2024年9月6日。董事會批准了一份行政僱傭協議,包括從2024年7月15日開始的67.5萬美元的初步基本工資、相當於基本工資60%的目標年度獎金以及購買60萬股股票的期權獎勵,每股27.42美元。這些期權將在四年內解鎖,取決於巴里的繼續僱傭。此外,協議規定了無正當理由解僱或出於正當理由辭職時的解聘福利,包括一年的基本工資和醫療計劃保障。僱傭協議的全部條款詳細列在附在修正案上的第10.1展示文檔中。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息